Literature DB >> 7963567

The second kappa B element, kappa B2, of the HLA-A class I regulatory complex is an essential part of the promoter.

P Mansky1, W M Brown, J H Park, J W Choi, S Y Yang.   

Abstract

The MHC class I regulatory complex (CRC) contains the well characterized palindromic kappa B element, kappa B1, to which a number of nuclear factors are known to bind. This cis element plays an important role in controlling the transcription of MHC class I genes. In addition, the CRC contains a second kappa B element, kappa B2, which is located in tandem with the kappa B1 site, 5 bp upstream. In this study, from reporter gene transfection experiments, we present evidence that this kappa B2 site is as important as kappa B1 in regulating HLA-A locus transcription. Mutations introduced into either kappa B site reduced promoter activity to approximately the level obtained when the entire CRC was deleted. Electrophoretic mobility shift and supershift assays showed that the kappa B2-binding complex (BIII) contained a p65-like subunit, but apparently not the p50 subunit of NF-kappa B. Complex BIII also bound to the kappa B1 site, but the kappa B2 sequence was poorly recognized by the kappa B1-binding complex, BI, probably KBF1, the p50 homodimer. These results demonstrate that both kappa B sites are essential components of the promoter and suggest that they may function together to control MHC class I gene transcription.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7963567

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  HLA-A and HLA-B transcription decrease with ageing in peripheral blood leucocytes.

Authors:  C Le Morvan; M Cogné; M Drouet
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

Review 2.  Expression of nonclassical MHC class Ib genes: comparison of regulatory elements.

Authors:  T Kevin Howcroft; Dinah S Singer
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

3.  The chicken BF1 (classical MHC class I) gene shows evidence of selection for diversity in expression and in promoter and signal peptide regions.

Authors:  Ann Marie O'Neill; Emily J Livant; Sandra J Ewald
Journal:  Immunogenetics       Date:  2009-02-11       Impact factor: 2.846

4.  A multiprotein complex consisting of the cellular coactivator p300, AP-1/ATF, as well as NF-kappaB is responsible for the activation of the mouse major histocompatibility class I (H-2K(b)) enhancer A.

Authors:  D Brockmann; B M Pützer; K S Lipinski; U Schmücker; H Esche
Journal:  Gene Expr       Date:  1999

5.  Cell surface expression of major histocompatibility complex class I molecules is reduced in hepatitis C virus subgenomic replicon-expressing cells.

Authors:  Keith D Tardif; Aleem Siddiqui
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

Review 6.  What is the role of alternate splicing in antigen presentation by major histocompatibility complex class I molecules?

Authors:  Alan Belicha-Villanueva; Jennifer Blickwedehl; Sarah McEvoy; Michelle Golding; Sandra O Gollnick; Naveen Bangia
Journal:  Immunol Res       Date:  2010-03       Impact factor: 2.829

7.  Tumor necrosis factor α-induced hypoxia-inducible factor 1α-β-catenin axis regulates major histocompatibility complex class I gene activation through chromatin remodeling.

Authors:  Sadashib Ghosh; Arkoprovo Paul; Ellora Sen
Journal:  Mol Cell Biol       Date:  2013-05-13       Impact factor: 4.272

8.  CREB-binding protein/p300 are transcriptional coactivators of p65.

Authors:  M E Gerritsen; A J Williams; A S Neish; S Moore; Y Shi; T Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

9.  Activation and homologous desensitization of human endothelial cells by CD40 ligand, tumor necrosis factor, and interleukin 1.

Authors:  K Karmann; W Min; W C Fanslow; J S Pober
Journal:  J Exp Med       Date:  1996-07-01       Impact factor: 14.307

10.  Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma.

Authors:  Anusha Kalbasi; Mito Tariveranmoshabad; Kevin Hakimi; Sarah Kremer; Katie M Campbell; Juan M Funes; Agustin Vega-Crespo; Giulia Parisi; Ameya Champekar; Christine Nguyen; Davis Torrejon; Daniel Shin; Jesse M Zaretsky; Robert D Damoiseaux; Daniel E Speiser; Pedro P Lopez-Casas; Marisol Quintero; Antoni Ribas
Journal:  Sci Transl Med       Date:  2020-10-14       Impact factor: 17.956

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.